In this video, health-care analyst David Williamson discusses why Biogen Idec's party may just be getting started despite a huge run in the stock already. It has two hemophilia drugs under FDA review, but more importantly, its new groundbreaking multiple sclerosis drug is surpassing even the highest expectations of its launch.
Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Started
May 19, 2013 | Comments (0)
DocumentId: 2439902, ~/Articles/ArticleHandler.aspx, 5/27/2016 8:15:30 PM